These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12516951)

  • 1. Ximelagatran. Exanta, H 376, H 376/95, H 37695.
    Drugs R D; 2002; 3(6):431-4. PubMed ID: 12516951
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ximelagatran for treatment of venous thromboembolism].
    Harenberg J; Fenyvesi T; Jörg I
    Hamostaseologie; 2002 Aug; 22(3):25-9. PubMed ID: 12215758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ximelagatran (AstraZeneca).
    Hopfner R
    Curr Opin Investig Drugs; 2002 Feb; 3(2):246-51. PubMed ID: 12020054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention and treatment of deep vein thrombosis with ximelagatran].
    Caspary L; Bauersachs R; Brehme S; Creutzig A; Harenberg J; Hoffmann U; Landgraf H; Schellong S
    Dtsch Med Wochenschr; 2004 Jul; 129(30):1635-40. PubMed ID: 15257504
    [No Abstract]   [Full Text] [Related]  

  • 5. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA; Dorrell KA; Sandberg KR; Yerkey MW
    Rev Cardiovasc Med; 2004; 5(2):99-103. PubMed ID: 15184843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
    N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism.
    Iorio A; Guercini F; Ferrante F; Nenci GG
    Curr Pharm Des; 2005; 11(30):3893-918. PubMed ID: 16305520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
    JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The METHRO trials.
    Hamaad A; Tayebjee MH; Lip GY
    Expert Opin Investig Drugs; 2003 May; 12(5):865-70. PubMed ID: 12720496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of THRIVE treatent study show that ximelagatran is safe and effective against throbosis.
    J Support Oncol; 2004; 2(1):56. PubMed ID: 15330373
    [No Abstract]   [Full Text] [Related]  

  • 12. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
    Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
    Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC; Perry CM; Faulds D
    Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A thrombin inhibitor called ximelagatran].
    Letonturier P
    Presse Med; 2005 Mar; 34(5):402. PubMed ID: 15859579
    [No Abstract]   [Full Text] [Related]  

  • 16. [Ximelagatran: hopes and controversies].
    Bressollette L
    J Mal Vasc; 2005 Jul; 30(3):142-3. PubMed ID: 16142177
    [No Abstract]   [Full Text] [Related]  

  • 17. [Ximelagatran (Exanta). Laboratory: Astra Zeneca].
    Moreno Alvarez PJ
    Farm Hosp; 2004; 28(2):146-8. PubMed ID: 15154414
    [No Abstract]   [Full Text] [Related]  

  • 18. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol.
    Sarich TC; Johansson S; Schützer KM; Wall U; Kessler E; Teng R; Eriksson UG
    J Clin Pharmacol; 2004 Apr; 44(4):388-93. PubMed ID: 15051746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ximelagatran for prevention and treatment of venous thromboembolism.
    Kwok L; Boucher M
    Issues Emerg Health Technol; 2004 Jun; (57):1-4. PubMed ID: 15214359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
    N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.